EMERYVILLE, Calif., July 31, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biotechnology company focused on the topical, anti-infective market, today announced that Thomas J. Paulson, Chief Financial Officer of NovaBay Pharmaceuticals, will present a corporate and clinical update at the Southern California Investor Conference, held on August 8, 2013 in Newport Beach, CA. Mr. Paulson will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.
|Event:||Southern California Investor Conference|
|Date:||Thursday, August 8, 2013|
|Time:||10:00 am PT|
|Place:||Newport Beach, CA|
To access the live audio webcast of this presentation, please log on through a link located in the News & Events section of NovaBay's website at http://novabay.com/investors/events. A replay of the webcast will be available one hour after the conclusion of the live event.
About NovaBay Pharmaceuticals, Inc.
Going Beyond Antibiotics
NovaBay Pharmaceuticals is a biotechnology company focused on addressing the large unmet therapeutic needs of the global, topical anti-infective market with auriclosene. The Company's four core business units – DermaBay, UroBay, EyeBay and MediBay – are developing products in dermatology, urology, ophthalmology, and wound care areas.
CONTACT: NovaBay Pharmaceuticals Contacts Thomas J. Paulson Chief Financial Officer 510-899-8809 email@example.com Ana Kapor Director, Investor Relations and Corporate Communications NovaBay Pharmaceuticals, Inc. 510-899-8889 firstname.lastname@example.orgSource:NovaBay Pharmaceuticals, Inc.